Some studies have shown that AMPK activation reduced myotonia, inhibited RNA toxicity, and enabled functional benefits via histological improvements, and therefore suggested targeted activation of AMPK signalling as a potential therapeutic approach (Brockhoff et al., 2017; Ravel-Chapuis et al., 2022; Ravel-Chapuis and Jasmin, 2022). The gene discussed is PRKAA2; the disease is Myotonia.